## Luciana Vinti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8523654/publications.pdf

Version: 2024-02-01

471509 395702 1,171 39 17 33 citations h-index g-index papers 39 39 39 2101 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 843.	7.4	166
2	Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplantation, 2011, 46, 200-207.	2.4	154
3	Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations. Haematologica, 2010, 95, 206-213.	3.5	78
4	Ex vivo expansion of mesenchymal stromal cells. Best Practice and Research in Clinical Haematology, 2011, 24, 73-81.	1.7	76
5	Treosulfanâ€based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. British Journal of Haematology, 2015, 169, 726-736.	2.5	68
6	The combination of bortezomib with chemotherapy to treatÂrelapsed/refractory acute lymphoblastic leukaemia of childhood. British Journal of Haematology, 2017, 176, 629-636.	2.5	56
7	Durable remissions in <i>TCF3-HLF</i> positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica, 2019, 104, e244-e247.	3.5	52
8	High frequency of ribosomal protein gene deletions in Italian Diamond-Blackfan anemia patients detected by multiplex ligation-dependent probe amplification assay. Haematologica, 2012, 97, 1813-1817.	3.5	49
9	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood, 2021, 137, 1582-1590.	1.4	48
10	TIM-3/Gal-9 interaction induces IFN $\hat{i}^3$ -dependent IDO1 expression in acute myeloid leukemia blast cells. Journal of Hematology and Oncology, 2015, 8, 36.	17.0	42
11	Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages. Journal of Immunology, 2017, 199, 1516-1525.	0.8	41
12	Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B ell Lymphoma treated with the <scp>AlEOP LNH</scp> â€97 protocol. British Journal of Haematology, 2016, 175, 467-475.	2.5	37
13	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica, 2019, 104, 1812-1821.	3.5	32
14	Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia, 2020, 34, 2473-2478.	7.2	26
15	Comprehensive characterization of mesenchymal stromal cells from patients with Fanconi anaemia. British Journal of Haematology, 2015, 170, 826-836.	2.5	23
16	The role of killer immunoglobulin-like receptor haplotypes on the outcome of unrelated donor haematopoietic SCT for thalassaemia. Bone Marrow Transplantation, 2010, 45, 1618-1624.	2.4	21
17	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia, 2022, 36, 1516-1524.	<b>7.</b> 2	21
18	Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma. Journal of Cancer, 2016, 7, 364-366.	2.5	18

#	Article	IF	CITATIONS
19	Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best Practice and Research in Clinical Haematology, 2011, 24, 339-349.	1.7	17
20	Eltrombopag for treatment of thrombocytopenia-associated disorders. Expert Opinion on Pharmacotherapy, 2015, 16, 2243-2256.	1.8	16
21	PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients. Pharmacogenomics Journal, 2020, 20, 415-425.	2.0	15
22	Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma. Oncotarget, 2017, 8, 107886-107898.	1.8	15
23	Cord blood transplantation in children with haematological malignancies. Best Practice and Research in Clinical Haematology, 2010, 23, 189-196.	1.7	12
24	Recurrent genetic fusions redefine <i>MLL </i> germ line acute lymphoblastic leukemia in infants. Blood, 2021, 137, 1980-1984.	1.4	12
25	Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage. Cancers, 2022, 14, 1540.	3.7	11
26	Comparison of Hodgkin's Lymphoma in Children and Adolescents. A Twenty Year Experience with MH'96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols. Cancers, 2020, 12, 1620.	3.7	10
27	Minimal residual disease analysis in childhood mature Bâ€cell leukaemia/lymphoma treated with AIEOP LNHâ€97 protocol with/without antiâ€CD20 administration. British Journal of Haematology, 2020, 189, e108-e111.	2.5	8
28	Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. Blood, 2017, 130, 2146-2149.	1.4	7
29	Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?. Cancers, 2022, 14, 1703.	3.7	7
30	Cord blood transplantation in children with hemoglobinopathies. Expert Opinion on Orphan Drugs, 2015, 3, 1125-1136.	0.8	5
31	HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma. Oncotarget, 2017, 8, 105957-105970.	1.8	5
32	Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. Pediatric Blood and Cancer, 2022, 69, e29557.	1.5	5
33	Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience. Diagnostics, 2021, 11, 1594.	2.6	4
34	Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a realâ€ife study. Pediatric Blood and Cancer, 0, , .	1.5	4
35	Repurposing anthelmintic agents to eradicate resistant leukemia. Blood Cancer Journal, 2020, 10, 72.	6.2	3
36	Poor prognosis of Bâ€cell acute lymphoblastic leukemia with ⟨i>TCF⟨ i>⟨i> ⟨i>⟨i>PBX1⟨ i> fusion gene and ovarian involvement at diagnosis: Two case reports and review of the literature. Pediatric Blood and Cancer, 2022, 69, e29299.	1.5	3

#	Article	IF	CITATIONS
37	Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience. Cancers, 2022, 14, 1471.	3.7	3
38	Chromosome anomalies in bone marrow as primary cause of aplastic or hypoplastic conditions and peripheral cytopenia: disorders due to secondary impairment of RUNX1 and MPL genes. Molecular Cytogenetics, 2012, 5, 39.	0.9	1
39	A Score for Predicting Freedom from Progression of Children and Adolescents with Hodgkin Lymphoma. Hemato, 2021, 2, 264-280.	0.6	O